The author got a fee from J&J/Janessen

But expecting $100mm peak revenue/yr?

From where?

Myocell?

HORNET DRIVER ON 09/12/16 08:10:26 PM

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125114683

THREE women BLINDED..FLORIDA stem clinic:

Last week was the intro "science sessions" at the FDA, preparing for the FDA's meetings today and tomorrow, for their "DRAFT GUIDANCE ON STEM CELLS" with what most believe is going to be their eventual efforts to "crack down" on rogue stem cell clinics operating on U.S. soil, offering NON FDA approved so called "stem cell treatments" and/or even promising "cures" via using primarily "fat" derived stem cells.

http://www.ipscell.com/2016/09/negative-stem-cell-clinic-outcomes-include-3-blinded-women/#comments

http://www.nature.com/news/boom-in-unproven-cell-therapies-intensifies-regulatory-debate-1.20545

"Thomas Albini, MD gave a talk entitled, “Severe Visual Loss After Intravitreal Injection of Autologous Adipose Tissue-derived Stem Cells for Age-related Macular Degeneration”."

A TOP, TOP of the line M.D., freaking Princeton, John Hopkins, Doheny Eye Institute of UCLA, an associate professor, an eye surgeon and eye medical clinic "expert of experts" from Florida, he presented a slide presentation and discussion on how he had to treat THREE, THREE woman who were caused to GO BLIND, after being injected into their eyes at a SOUTH FLORIDA BASED "stem cell clinic" using "fat derived stem cells" and done via a "nurse practitioner". They were then sent to him to see what he could "salvage" of their eyes, and eye sight.

That eye doctor's resume/credentials reads like a who's who of world leading eye experts- he's practiced and trained at some of the finest universities in the country AND the Doheny Eye Institute in Southern CA (affiliated with UCLA, which interestingly, is where Sam Ahn, one of USRM BOD that just quit, a university hospital center he's affiliated with), this Dr. Albini has worked/trained at one of the world's most respected eye research and treatment centers. So this guy knows his sh@t down cold.

NO sh@t, this is STUNNING, STUNNING info. Put the freaking puzzle pieces together- and one has a hard time not believing this might be U.S. Stem Cell Clinic, aka USRM's little clinic biz they now own 1/3 of and boast all the time about. I'm trying to get confirmation and prove if, or if it is not U.S. Stem Cell, but look at the facts:

1) U.S. Stem Cell Clinic is located in SOUTH FLORIDA

2) U.S. Stem Cell Clinic was sued in Broward County 17th circuit court for what? SUPPOSEDLY CAUSING BLINDNESS in at least two women named in the case. Broward County Case Number: CACE15021101, Andrew Yaffa lead plaintiff attorney, Grossman Roth Yaffa Cohen law firm.

3) The case documents, especially the lengthy original plaintiff complaint "as filed" on the public access portal alleged the "treatments" were done BY A NURSE PRACTITIONER (named in the case) and not an "M.D." EXACTLY as was described in the FDA presentation by Dr. Albini in his slide presentation and discussion a few days ago. WHAT'S THE FREAKING ODDS OF THAT?

4) The cells used were FAT derived stem cells- also exactly matching the civil case as described and filed against U.S. Stem Cell Clinic

5) Kristin Comella is ON VIDEO, captured and preserved forever, speaking at a "conference" type event in Dec of 2015 and she's talking about their clinic biz. She's asked about "side effects" and stuff. PARAPHRASING, "NO, NONE...well, you know, except the EYE RELATED STUFF, so of course we've STOPPED ANY OF THAT..NO MORE doing the "eye" procedures stuff... you know, cause of what happened". PARAPHRASING. It's on Youtube, she said it. She said they had some sort of adverse "EYE" things happen at their clinic and we know a civil lawsuit was also filed, alleging BLINDNESS by at least two women- and that USRM and their clinic's insurance appear to have "settled" those cases out of court, per the Broward 17th circuit public access portal case documents.

6) The Dr, Dr Albini alleges that the patients were told the procedure was "legit" and "safe" by the stem cell clinic, as they were pointed to and shown a "clinical trial" filed on the U.S. gov clinical trials site, BUT, that the patients were never enrolled in said trial, AND, the "trial" didn't look of high quality, only being per some "institutional review board" and NOT the FDA itself. WELL, SHAZAM, one checks for a exhaustive search of clinicaltrials.gov, and what comes up matching that description- BIOHEART, aka U.S. Stem Cell, that's what I found, ME ONLY at least, per my own searching.

https://clinicaltrials.gov/ct2/show/NCT02024269?term=bioheart&rank=2

Again, I'M NOT SAYING I KNOW THAT THIS Dr. Albini and THREE BLIND WOMEN are for sure speaking of, or saying this occurred at "U.S. Stem Cell Clinic", but there sure as sh@t are a lot of things that make it look like it very well could be them. I did a exhaustive search using Google of Florida stem cell "eye" related clinics, clinical trials, etc and only came up with ONE, ONE other "clinic" near "South Florida" and they're doing "bone marrow" stem cell "eye" related stuff of some sort, NOT FAT, as U.S. Stem Cell does.

Again, I'm gonna try and make contacts with people who may "know" or can confirm this 100% and will pursue it as far as I can- as I think it's stunning to say the least IMO.

What I think can make this REALLY "big" in terms of a case (FDA, who knows what other agencies) is that this Dr Albini stated in a public forum, that per his knowledge per interviewing the patients, AFTER THEY'D BEEN MADE BLIND via the fat "stem cells" wrecking their eyes, was that they were MISLED, MISLED by being pointed to the "clinical trials" site, as if that was "validation" that what was about to be done to them (a NON FDA APPROVED PROCEDURE) that it was somehow "safe". THAT to me again, is beyond stunning.

I'm gonna try and get this M.D.'s (Albini) his full slide show and even audio or a transcript if it's available and I know "others" who are trying to get the name of the stem cell clinic revealed and 100% confirmed.

AGAIN, I DO NOT KNOW FOR SURE if this was U.S. Stem Cell Clinic- but SOUTH FLORIDA (aka Sunrise is SOUTH as one can get), a CIVIL LAWSUIT filed that reads like the M.D.'s presentation to the FDA, almost word for word, Comella's public comments of "EYE PROBLEMS AT THEIR CLINIC, causing them to cease any of that "eye type stuff"", a NURSE PRACTITIONER administering said "stem cell eye treatment" again PERFECT MATCH to the Broward court case docs as filed against USRM and their "clinic" and on and on and on- PERFECT PUZZLE PIECES IMO.

REGARDLESS, it shows that this "FAT STEM CELLS ARE "SAFE" and do not need FDA approval blah, blah, blah" is pure BULL EXCREMENT IMO. BLINDNESS is just one of the many "adverse" bad outcomes, that were presented to the FDA over the past several days- some REALLY, REALLY bad sh@t was shown to have been done to CASH PAYING, innocent, desperate people at these "rogue" clinics who are offering NON FDA APPROVED "treatments", via a vague interpretation of one particular wording of the law. Comella of USRM is "on the record", captured ON VIDEO in late 2015 (it's on Youtube) stating (PARAPHRASING), "I guess a lot of what I'm going to talk about is controversial and certainly in that "gray" area of regulations or the law" (pretty much those words, I can transcribe it word for word, when I get time, but the video is easily found vie looking for Comella stem cell summit on Youtube, just watch her speak and see for yourself)

I'm gonna try and find out all I can- that's just me and these are MY OPINIONS and MINE ONLY and MY FACTS/DATA as I FOUND THEM ON THE WEB, AND NO ONE ELSE'S. IGNORE THEM, read them, flush um down the toilet- whatever one wants to do with them. And DO NOT make a investing decision based on anything I write or wrote, again, this is just my personal things I'm choosing to research and look in to. I'm sharing it cause I know people like Poor Man- and some others may not know about it, but may be very interested in reading all the links, reading what this Dr Albini (a certain medical expert) had to say and may want the info for future use, just in case "needed" for ANY reason(s) at all :))

http://californiahealthline.org/news/fda-wants-to-tighten-the-screws-on-stem-cell-clinics/

http://www.ipscell.com/2016/09/guide-september-12-13-fda-stem-cell-meeting-top-10-bullet-points/

Is there any amounts paid for M&A such as the 11mm for a failed M&A?
There should be some amount,right?.

Somebody seriously want all the shares

USRM link on google finance is gone.

The article was prepared in October 2016 and the author was paid by J&J.

Item 3. Legal Proceedings from 10-k filed today

On September 17, 2015, a product liability lawsuit was filed in Broward County, specifically Patsy Bade v. Bioheart, Inc. US Stem Cell Clinics LLC, Aleiandro Perez, ARNP, and Shareen Greenbaum, M.D., and on November 30, 2015, a product liability lawsuit was filed in Broward County, specifically Elizabeth Noble v. Bioheart, Inc. US Stem Cell Clinics LLC, Aleiandro Perez, ARNP, and Shareen Greenbaum, M.D. During the year ended December 31, 2016, both matters settled by the Company’s insurance policy with no additional cost to the Company.

On February 8, 2016, a collection lawsuit was filed in Broward County, specifically Roche Diagnostics Corp. v. U.S. Stem Cell, Inc., demanding judgement against the Company for an aggregate of $42,246 plus interest and costs for alleged unpaid product. During the year ended December 31, 2016, the Company settled all matters for a net payment of $8,500.

On August 30th, 2016 Northstar Biotech Group, LLC (“NorthStar”) filed suit against the Company seeking a declaratory judgment as to whether its 20,000,000 Series A Preferred Shares were the subject of the Company’s reverse stock split effective November 4, 2015.

On March 1, 2017, Northstar and the Company entered into a settlement agreement related to this dispute (the “Settlement Agreement”). Pursuant to the terms and conditions of the Settlement Agreement, Northstar, previously a holder of Company preferred stock, has converted such preferred stock to twenty million (20,000,000) shares of common stock. In addition, and separate and apart from the conversion, Northstar will receive Ten Million (10,000,000) shares of common stock. NorthStar will receive ten percent (10%) of all Company international sales (based on a gross sales basis). Furthermore, a NorthStar designee, Greg Knutson, was appointed to the Board of Directors of the Company (see Item 5.02) and two Company directors, Michael Tomas and Kristin Comella, will each exercise their prior NorthStar options to each receive a Five percent (5%) Member Interest in NorthStar. The parties agreed to a mutual release and NorthStar agreed to terminate any UCC lien on the Company assets previously filed for the benefit of NorthStar.

The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity. There was no outstanding litigation as of December 31, 2016 other then described above.

New England Journal Of Medicine Original article in Oct 2016

Read the disclosure forms in the middle of the page.

Read page 2/31

Author
Thomas Albini


Date Oct 18,2016

Manuscript Title
Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD

The author was paid by
J&J/Janssen Cell Therapy Org.
Comments:
Consulting for company developing
surgical delivery system for stem cell
therapy

http://www.nejm.org/doi/full/10.1056/NEJMoa1609583?query=featured_home

10-K covers before 2017

The Company’s primary source of revenue is from the sale of test kits and equipment, training services, patient treatments and laboratory services, and cell banking. Our revenue may vary substantially from quarter to quarter and from year to year. We believe that period-to-period comparisons of our results of operations are not meaningful and should not be relied upon as indicative of our future performance. We do not expect to generate substantial revenues until we obtain regulatory approval for and commercialize our product candidates, which we do not expect to occur before 2017

NIH paper on MYOCELL Phases 1 2 3

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668534/

They will talk about assurance,proxy 2017 and employee awards(they wont publicly though).That is my expectation.WMIH could be delisted down the line imho.Probably that is the plan of the big fish,PE firm and trumpet BOD.Its amazing to see both Appaloosa and MW have same interests in WMIH.They became friends now.

For Type-2 Diabetes

Does any one know they still do this?.If it is a success, its huge for this company and shareholders IMHO.

Patient-Sponsored Study [7]
This is a study which use autologous stem cells harvested from adipose tissue to treat Type 2
diabetes. It is being conducted by the US based company Bioheart (now called U.S. Stem Cell
Clinic) and they estimated that two-thirds of participants will experience a significant
improvement and symptom reduction. Patients that are eligible for this treatment are any that
suffered of diabetes type-2. The procedure is divided in four stages and it is performed at the
doctor’s office. The stages are:
Adipose harvest: A mini liposuction is performed in the stomach to extract a small
amount of adipose tissue; this tissue contain tens of millions of adipose stem cells [7].
- Laboratory processing: The extracted stem cells will be isolated, analyzed, clean and
concentrated [7].
- Stem Cell Implantation: Up to 60 million stem cells will be transplanted to the patient.
Rejection risk is minimal since the cells are autologous [7].
- Postoperative care: Participants will leave after the procedure and RSCI will check the
progress of the patient on a monthly basis for the first year after the treatment [7].
This is a patient-sponsored study and the cost of the treatment and the follow-up care is $5,000.
This treatment can be done in other centers worldwide but it will cost more. The participation is
limited to 100 Type-2 Diabetes patients.

Can somebody put this in sticky.Thanks.

USRM on FDA conference with Johnson & Johnson and other companies

https://www.fda.gov/biologicsbloodvaccines/newsevents/workshopsmeetingsconferences/ucm509279.htm

Part 15 Hearing: Draft Guidances Relating to the Regulation of Human Cells, Tissues, or Cellular or Tissue-Based Products

September 12-13, 2016
National Institutes of Health (NIH)
9000 Rockville Pike, Building 10, Masur Auditorium
Bethesda, MD 20892

Panel Members

Celia M. Witten, Ph.D., M.D., Presiding Officer
Deputy Director
Center for Biologics Evaluation and Research
Food and Drug Administration

Mary A. Malarkey
Director
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research
Food and Drug Administration

Diane M. Maloney, J.D.
Associate Director for Policy
Center for Biologics Evaluation and Research
Food and Drug Administration

Angela C. Krueger
Associate Director for Guidance and Regulations
Office of Device Evaluation
Center for Devices and Radiological Health
Food and Drug Administration

Sheryl Lard-Whiteford, Ph.D.
Associate Director for Quality Assurance
Center for Biologics Evaluation and Research
Food and Drug Administration

John B. Weiner
Associate Director for Policy
Office of Combination Products
Food and Drug Administration

Rachael F. Anatol, Ph.D.
Associate Director of Policy
Office of Cellular, Tissue and Gene Therapies
Center for Biologics Evaluation and Research
Food and Drug Administration

Denise Zavagno, J.D.
Senior Counsel
Office of the Chief Counsel
Food and Drug Administration

Agenda

September 12, 2016

9:00-9:10: Presiding Officer Opening Remarks and Introduction of Panel Members

9:10-10:57: Session 1

9:10-9:15: Alliqua Biomedical
9:16-9:21: Allosource
9:22-9:27: Atlanta Medical Center
9:28-9:33: Birth Tissue Recovery, LLC
9:34-9:39: INCELL Corporation LLC
9:40-9:45: Intellicell BioSciences
9:46-9:51: Johnson & Johnson
9:52-9:57: Kerastem Technologies
9:58-10:03: LifeLink Tissue Bank
10:04-10:09: LifeNet Health
10:10-10:15: MedCentris
10:16-10:21: Millennium Medical Technologies
10:22-10:27: MiMedx Group, Inc.
10:28-10:33: Musculoskeletal Transplant Foundation
10:34-10:39: Organogenesis
10:40-10:45: RTI Surgical
10:46-10:51: StemGenex Inc
10:52-10:57: US Stem Cell Inc

10:57-11:07: Questions from Panel

11:07-11:27: Break

11:27-11:57: FDA presentation on September 8, 2016 workshop “Scientific Evidence in Development of HCT/Ps Subject to Premarket Approval”

11:57-1:12: Lunch: Ala Carte items will be available for purchase on site

1:12-2:29: Session 2

1:12-1:17: Boston College Law School
1:18-1:23: Case Western University
1:24-1:29: Indiana University School of Medicine
1:30-1:35: NYU Langone Medical Center
1:36-1:41: Wake Forest University School of Medicine
1:42-1:47: Alston & Bird LLP
1:48-1:53: Navigant Consulting
1:54-1:59: OrthoKinetic Technologies, LLC
2:00-2:05: Parenteau BioConsultants
2:06-2:11: California Stem Cell Treatment Center and Cell Surgical Network
2:12-2:17: Celebration Stem Cell Center
2:18-2:23: Long Island Plastic Surgical Group
2:24-2:29: National Spine and Pain Centers-VA

2:29-2:39: Questions from panel

2:39-4:49: Session 3

2:39-2:47: Academy of Regenerative Practices
2:48-2:56: Alliance for Regenerative Medicine
2:57-3:05: Alliance for the Advancement of Cellular Therapies
3:06-3:14: Alliance of Wound Care Stakeholders

3:14-3:29: Break

3:29-3:37: American Association of Blood Banks
3:38-3:46: American Association of Tissue Banks
3:47-3:55: American College of Surgeons
3:56-4:04: American Society of Plastic Surgeons
4:05-4:13: Biologic Orthopedic Society
4:14-4:22: Bipartisan Policy Center
4:23-4:31: California Institute for Regenerative Medicine
4:32-4:40: California Life Sciences Association
4:41-4:49: Coalition of Wound Care Manufacturers

4:49-4:59: Questions from Panel

4:59-close: Closing remarks/adjournment

September 13, 2016

9:00-9:14: Presiding Officer Opening Remarks and Introduction of Panel Members

9:14-10:43: Session 3, Continued

9:14-9:22: Foundation for the Accreditation of Cellular Therapy
9:23-9:31: Info Health Global
9:32-9:40: Institute for Regenerative and Cellular Medicine
9:41-9:49: International Federations for Adipose Therapeutics and Science
9:50-9:58: International Society for Cellular Therapy
9:59-10:07: International Society for Stem Cell Research
10:08-10:16: National Center for Health Research
10:17-10:25: The Cord Blood Association
10:26-10:34: The Cure Alliance
10:35-10:43: The Plastic Surgery Foundation

10:43-10:53: Questions from Panel

10:53-11:08: Break

11:08-4:46: Session 4

11:08-11:13: Waldo Acebo
11:14-11:19: Rebecca Baergen
11:20-11:25: Harold Brem
11:26-11:31: Julie Cerrone
11:32-11:37: Kara Couch
11:44-11:49: Georgianna Crocker
11:50-11:55: Fiona Cunningham
11:56-12:01: Roxana Daftarian
12:02-12:07: Rahul Desai
12:08-12:13: Yoelma Eid Sandoval
12:14-12:19: Ryan Fitzgerald

12:19-1:34: Lunch: Ala Carte items will be available for purchase on site

1:34-1:39: Timothy Freeman
1:40-1:45: Brian Gates
1:46-1:51: Marie Gehling
1:52-1:57: Ted Gradel
1:58-2:03: R. Scott Graham
2:04-2:09: Sarah Hughes
2:10-2:15: Scott James
2:16-2:21: Kristen King
2:22-2:27: John Klimkiewicz
2:34-2:39: Jeanne Loring
2:40-2:45: Norman Marcus
2:46-2:51: Brian Marr
2:52-2:57: Kristen Marr
2:58-3:03: Carl Nicastro
3:04-3:09: Michael Sabolinski
3:10-3:15: Sheila Sabon DeCastro
3:16-3:21: Carolyn Salafia

3:21-3:41: Break

3:41-3:46: John Samies
3:47-3:52: George Sauter
3:53-3:58: Rosemary Tambouret
3:59-4:04: Tracy Thompson
4:05-4:10: Amy Tucker
4:11-4:16: Leigh Turner
4:17-4:22: Eliza Tyler
4:23-4:28: Newton Vaughn
4:29-4:34: Samantha Wilkinson
4:35-4:40: Joan Woodward
4:41-4:46: Jennifer Ziegler

4:46-4:56: Questions from Panel

4:56-close: Closing remarks/adjournment

FDA Final Agenda: Part 15 Hearing: Draft Guidances Relating to the Regulation of Human Cells, Tissues, or Cellular or Tissue-Based Products

https://www.fda.gov/biologicsbloodvaccines/newsevents/workshopsmeetingsconferences/ucm509279.htm

Part 15 Hearing: Draft Guidances Relating to the Regulation of Human Cells, Tissues, or Cellular or Tissue-Based Products


September 12-13, 2016
National Institutes of Health (NIH)
9000 Rockville Pike, Building 10, Masur Auditorium
Bethesda, MD 20892

Panel Members

Celia M. Witten, Ph.D., M.D., Presiding Officer
Deputy Director
Center for Biologics Evaluation and Research
Food and Drug Administration

Mary A. Malarkey
Director
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research
Food and Drug Administration

Diane M. Maloney, J.D.
Associate Director for Policy
Center for Biologics Evaluation and Research
Food and Drug Administration

Angela C. Krueger
Associate Director for Guidance and Regulations
Office of Device Evaluation
Center for Devices and Radiological Health
Food and Drug Administration

Sheryl Lard-Whiteford, Ph.D.
Associate Director for Quality Assurance
Center for Biologics Evaluation and Research
Food and Drug Administration

John B. Weiner
Associate Director for Policy
Office of Combination Products
Food and Drug Administration

Rachael F. Anatol, Ph.D.
Associate Director of Policy
Office of Cellular, Tissue and Gene Therapies
Center for Biologics Evaluation and Research
Food and Drug Administration

Denise Zavagno, J.D.
Senior Counsel
Office of the Chief Counsel
Food and Drug Administration

Agenda

September 12, 2016

9:00-9:10: Presiding Officer Opening Remarks and Introduction of Panel Members

9:10-10:57: Session 1

9:10-9:15: Alliqua Biomedical
9:16-9:21: Allosource
9:22-9:27: Atlanta Medical Center
9:28-9:33: Birth Tissue Recovery, LLC
9:34-9:39: INCELL Corporation LLC
9:40-9:45: Intellicell BioSciences
9:46-9:51: Johnson & Johnson
9:52-9:57: Kerastem Technologies
9:58-10:03: LifeLink Tissue Bank
10:04-10:09: LifeNet Health
10:10-10:15: MedCentris
10:16-10:21: Millennium Medical Technologies
10:22-10:27: MiMedx Group, Inc.
10:28-10:33: Musculoskeletal Transplant Foundation
10:34-10:39: Organogenesis
10:40-10:45: RTI Surgical
10:46-10:51: StemGenex Inc
10:52-10:57: US Stem Cell Inc

10:57-11:07: Questions from Panel

11:07-11:27: Break

11:27-11:57: FDA presentation on September 8, 2016 workshop “Scientific Evidence in Development of HCT/Ps Subject to Premarket Approval”

11:57-1:12: Lunch: Ala Carte items will be available for purchase on site

1:12-2:29: Session 2

1:12-1:17: Boston College Law School
1:18-1:23: Case Western University
1:24-1:29: Indiana University School of Medicine
1:30-1:35: NYU Langone Medical Center
1:36-1:41: Wake Forest University School of Medicine
1:42-1:47: Alston & Bird LLP
1:48-1:53: Navigant Consulting
1:54-1:59: OrthoKinetic Technologies, LLC
2:00-2:05: Parenteau BioConsultants
2:06-2:11: California Stem Cell Treatment Center and Cell Surgical Network
2:12-2:17: Celebration Stem Cell Center
2:18-2:23: Long Island Plastic Surgical Group
2:24-2:29: National Spine and Pain Centers-VA

2:29-2:39: Questions from panel

2:39-4:49: Session 3

2:39-2:47: Academy of Regenerative Practices
2:48-2:56: Alliance for Regenerative Medicine
2:57-3:05: Alliance for the Advancement of Cellular Therapies
3:06-3:14: Alliance of Wound Care Stakeholders

3:14-3:29: Break

3:29-3:37: American Association of Blood Banks
3:38-3:46: American Association of Tissue Banks
3:47-3:55: American College of Surgeons
3:56-4:04: American Society of Plastic Surgeons
4:05-4:13: Biologic Orthopedic Society
4:14-4:22: Bipartisan Policy Center
4:23-4:31: California Institute for Regenerative Medicine
4:32-4:40: California Life Sciences Association
4:41-4:49: Coalition of Wound Care Manufacturers

4:49-4:59: Questions from Panel

4:59-close: Closing remarks/adjournment

September 13, 2016

9:00-9:14: Presiding Officer Opening Remarks and Introduction of Panel Members

9:14-10:43: Session 3, Continued

9:14-9:22: Foundation for the Accreditation of Cellular Therapy
9:23-9:31: Info Health Global
9:32-9:40: Institute for Regenerative and Cellular Medicine
9:41-9:49: International Federations for Adipose Therapeutics and Science
9:50-9:58: International Society for Cellular Therapy
9:59-10:07: International Society for Stem Cell Research
10:08-10:16: National Center for Health Research
10:17-10:25: The Cord Blood Association
10:26-10:34: The Cure Alliance
10:35-10:43: The Plastic Surgery Foundation

10:43-10:53: Questions from Panel

10:53-11:08: Break

11:08-4:46: Session 4

11:08-11:13: Waldo Acebo
11:14-11:19: Rebecca Baergen
11:20-11:25: Harold Brem
11:26-11:31: Julie Cerrone
11:32-11:37: Kara Couch
11:44-11:49: Georgianna Crocker
11:50-11:55: Fiona Cunningham
11:56-12:01: Roxana Daftarian
12:02-12:07: Rahul Desai
12:08-12:13: Yoelma Eid Sandoval
12:14-12:19: Ryan Fitzgerald

12:19-1:34: Lunch: Ala Carte items will be available for purchase on site

1:34-1:39: Timothy Freeman
1:40-1:45: Brian Gates
1:46-1:51: Marie Gehling
1:52-1:57: Ted Gradel
1:58-2:03: R. Scott Graham
2:04-2:09: Sarah Hughes
2:10-2:15: Scott James
2:16-2:21: Kristen King
2:22-2:27: John Klimkiewicz
2:34-2:39: Jeanne Loring
2:40-2:45: Norman Marcus
2:46-2:51: Brian Marr
2:52-2:57: Kristen Marr
2:58-3:03: Carl Nicastro
3:04-3:09: Michael Sabolinski
3:10-3:15: Sheila Sabon DeCastro
3:16-3:21: Carolyn Salafia

3:21-3:41: Break

3:41-3:46: John Samies
3:47-3:52: George Sauter
3:53-3:58: Rosemary Tambouret
3:59-4:04: Tracy Thompson
4:05-4:10: Amy Tucker
4:11-4:16: Leigh Turner
4:17-4:22: Eliza Tyler
4:23-4:28: Newton Vaughn
4:29-4:34: Samantha Wilkinson
4:35-4:40: Joan Woodward
4:41-4:46: Jennifer Ziegler

4:46-4:56: Questions from Panel

4:56-close: Closing remarks/adjournment

Which companies are included on the SRO List?

A publicly traded company, US or foreign stock exchange, is added to the SRO List if it meets either of the following criteria:

It is an organization for which the sales of products regulated by the Food and Drug Administration (FDA) constitute ten percent or more of annual gross sales in the organization's previous fiscal year;
An organization that does not have a record of sales of FDA-regulated products will be deemed to be significantly regulated if its operations are predominately in fields regulated by FDA, or if its research, development, or other business activities are reasonably expected to result in the development of products that are regulated by FDA.

Thanks for sharing the link.

Some have to hold atleast for 7 years IMHO.Check it though.If that is the case, 2019 is the magic year on par with Zelin's projections of WMIH, all just my opinion.And management and LT trustee are very careless about present and past shareholders.

FROM LAST 10-Q
On January 29th, 2015 we announced an update and diversification of our clinical development pipeline. Our cardiovascular and vascular product candidates have been streamlined, putting, we believe, our best opportunities at the forefront of our efforts. The MYOCELL and MYOCELL SDF-1 candidates will, in our opinion, advance forward in the treatment of chronic heart failure (CHF). We are in active prospective partnering discussion for the MYOCELL SDF-1 program. Partnering, we contend, will enhance our capabilities, reduce our development cost through cost sharing and potentially accelerate our time to approval and commercialization. We will apply our ADIPOCELL to a variety of indications. We believe that updating and diversifying our clinical development programs increases the probability of our success, brings operational and fiscal clarity to our company, and will ultimately enhance shareholder value.

Probably class 18 claims have been resolved, yet to see filings from PPM America..etc

JP you asked every one to short this stock in this forum.And my post got deleted too, which you responded.

It is not Grey listed.It appears on OTCmarkets as grey,bids/ask not showing up.

Sorry, wrong board.

MW on LT TAB - LTIs for Escrows

From Sept opinion

In addition, the
composition of the Trust Advisory Board must reflect the
constituents who hold Liquidating Trust Interests. When
creditors are paid in full, their Liquidating Trust Interests
will be canceled and preferred shareholders will be issued
Liquidating Trust Interests.

Does n't mean that equity got LTIs?

that the Modified 11
Plan provides that the TPS will be transferred pursuant to
section 363 to JPMC, which will be a good faith purchaser and
entitled to the protections of section 363(m).
Sept opinion page18/148

So if TPS was transferred pursuant to 363, it was never transferred to JPM pursuant to P&A?

Dont know what happened to the 11B assets related to TPS?

Tranquility Lawyer with drawn from the case.

They had seat in the trust.

Probably some thing brewing on the Escrow side?.

They made it to Phase 3 in 2015

120Million into the product for clinical trials

Kristin Comella

WSCS 2015: Training Physicians for Regenerative Medicine Practice HD

Around 2.40

AMBS stopped filings for a long time and now the company is in Grey.

No bids and asks, which is good in a way for longs,IMHO.

Proof please

Elto has been in Ph3 IMHO

http://adisinsight.springer.com/trials/700276046?query=all%3A%28%22Amarantus+Bioscience%22%29

Ongoing trial

As per 8K 5% For Mike and 5% Kirstin of total contribution
of 30million shares to Northstar,right?

These guys are accumulating their shares....

Myocell already in south korean market?

http://www.ancbio.com/en/01_main/index.asp#

FORM3s for new team mean LOI is confirmed?

Is it not?

It is, IMHO.

Name/Title Total Shares Held TTM Change % Shares Outstanding % Market Value

All Key Insiders 59,897,598 1,538.14% 100.53% 1,874,795

Samuel S. Ahn
Independent Director 28,240,387 100.43 47.4% 883,924

William P. Murphy
Chairman of the Board 13,942,848 6,385.53 23.4% 436,411

Charles A. Hart
Independent Director 9,194,422 28.51 15.43% 287,785

Mike Tomas
Director, President, Chief Executive Officer and Chief Financial Officer 6,578,947 0 11.04% 205,921

Sheldon T. Anderson
Director 1,940,994 0 3.26% 60,75

http://insiders.morningstar.com/trading/insider-activity.action?t=USRM®ion=usa&culture=en-US&ownerCountry=USA

125MM put into research, incredible.

Mike Tomas interview on youtube mentioned that he was looking for a Billion dollar opportunity with this company.

125mm was put into action and the market cap is 1.58mm , very laughable.

Not even a single document on the epiq docket

5th anniversary of LAMCO

case getting closer?

March 6th,5th year completion of LAMCO as promised

No docket activity?

I want to see which one in particular is relevant to Cts or How this confirmed indenture is related to Cts?
++++++++++++++++++++++++++++++++++++
So you have no clue?.
Why do you think BNYM as an Indenture trustee filed the claims?
++++++++++++++++++++++++++++++++++++

Debentures were issued to Indenture Trust based upon an agreement which is called as Indenture with the Indenture Trustee(BNYM).Debentures are not a property, but its kind of IOU.Property Trust issued CTs and Commons to public and LBHI respectively.In the case of default or liquidation, the debentures held by the Indenture Trust should be distributed to CT holders, forget about commons because those shares were held by LBHI.

You are correct.Now the Indenture and property trustee is BNY Mellon, i got the confirmation from the vice president of BNY Trust services.His name is Gary Bush.